TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31442250

Group type: EXPERIMENTAL
Intervention: Shareholder networks in Turkish companies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shareholder networks in Dutch companies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised version of shareholder networks
Number of subjects: 0
Study: 29663044

Group type: EXPERIMENTAL
Intervention: 5-day PCT algorithm with predefined cutoff values for the initiation or stoppage of antibiotics (PCT group)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Standard guidelines (control group)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: PCT group
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 302
Study: 26469139

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (doxorubicin-cyclophosphamide followed by weekly paclitaxel) in arm A
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab (doxorubicin-cyclophosphamide followed by weekly paclitaxel plus trastuzumab) in arm C
Number of subjects: 945
Study: 23385488

Group type: EXPERIMENTAL
Intervention: Behavioral telephonic intervention
Number of subjects: 526

Group type: COMPARATOR
Intervention: Print only intervention
Number of subjects: 526
Study: 23426208

Group type: EXPERIMENTAL
Intervention: Epidural Analgesia (EA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous Wound Infiltration (CWI)
Number of subjects: 50
Study: 20010606

Group type: EXPERIMENTAL
Intervention: Non-invasive technique targeting reconsolidation of fear memories
Number of subjects: 0
Study: 17678558

Group type: EXPERIMENTAL
Intervention: MeNZB+MenC
Number of subjects: 0

Group type: COMPARATOR
Intervention: MeNZB
Number of subjects: 0
Study: 16620720

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 102
Study: 12797485

Group type: EXPERIMENTAL
Intervention: Hospital-acquired pneumonia (HAP)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Community-acquired pneumonia (CAP)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Acute exacerbation of chronic bronchitis (AECB)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Tuberculosis
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (noninfectious lung diseases)
Number of subjects: 129
Study: 11001085

Group type: EXPERIMENTAL
Intervention: MPA 60 mg daily for 14 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 8803515

Group type: EXPERIMENTAL
Intervention: Moexipril 7.5 mg o.d.
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Moexipril 15 mg o.d.
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg o.d.
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 1730810

Group type: EXPERIMENTAL
Intervention: Transdermal E2 and vaginal P (group I, n = 11)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: P only (group II, n = 11)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No E2 or P (group III, n = 9)
Number of subjects: 31
Study: 31944806

Group type: EXPERIMENTAL
Intervention: RNT-focused acceptance and commitment therapy (ACT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 48
Study: 30639922

Group type: EXPERIMENTAL
Intervention: PATCH (100 mcg transdermal 17β-estradiol with cyclic progesterone)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: PILL (30 mcg ethinyl estradiol + 0.15 mg desogestrel)
Number of subjects: 117

Group type: COMPARATOR
Intervention: E- (no estrogen)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: PATCH
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: PILL
Number of subjects: 117
Study: 27077214

Group type: EXPERIMENTAL
Intervention: Means Safety
Number of subjects: 370

Group type: COMPARATOR
Intervention: Means Restriction
Number of subjects: 370
Study: 25765132

Group type: EXPERIMENTAL
Intervention: Porous tantalum monoblock cup (TM)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Porous-coated titanium monoblock cup (control)
Number of subjects: 113
Study: 23815533

Group type: EXPERIMENTAL
Intervention: Weight loss maintenance strategy
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Weight stable group
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Weight gain group
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 741
Study: 21371991

Group type: EXPERIMENTAL
Intervention: Multimedia mobile phone intervention (STUB IT) with automated video and text messages tailored to quit date, role model, and timing over 6 months.
Number of subjects: 226

Group type: COMPARATOR
Intervention: General health video message sent to control group every 2 weeks.
Number of subjects: 226
Study: 19762153

Group type: EXPERIMENTAL
Intervention: Tramadol 100mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pregabalin 100mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17359512

Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion (CsA‐ME)
Number of subjects: 682

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 682
Study: 15251156

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine treatment
Number of subjects: 415

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 415
Study: 12514902

Group type: EXPERIMENTAL
Intervention: Testicular torsion
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Antisperm antibodies
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CD4+, CD8+, and NK cells
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: LH and/or FSH and/or testosterone levels
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hormonal function
Number of subjects: 37
Study: 9725548

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.6 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.8 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7976643

Group type: EXPERIMENTAL
Intervention: Mild cerebral hypothermia (32-33 degrees C) managed by whole body compartment cooling technique
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous monitoring of jugular venous oxygen saturation and BTT/TMT during cerebral hypothermia treatment
Number of subjects: 10
Study: 2647187

Group type: EXPERIMENTAL
Intervention: rh GM‐CSF (recombinant human granulocyte/macrophage colony stimulating factor) administered by continuous infusion for 3‐21 days at doses of 100‐400 micrograms/m2/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no rh GM‐CSF)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: rh GM‐CSF
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 30636747

Group type: EXPERIMENTAL
Intervention: Posttraumatic Embitterment Scale (PTED scale)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: General Health Questionnaire (GHQ‐28)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Survey on unemployment status
Number of subjects: 102
Study: 28221207

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 2496

Group type: COMPARATOR
Intervention: Tranexamic acid (TXA)
Number of subjects: 2496
Study: 26467326

Group type: EXPERIMENTAL
Intervention: Expressive writing (n = 508)
Number of subjects: 1292
Study: 23706644

Group type: EXPERIMENTAL
Intervention: IV lidocaine (2mg/kg of 2% lidocaine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TEA lidocaine (0.15 mL/kg of 1.35% lidocaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (0.9% normal saline)
Number of subjects: 60
Study: 21875912

Group type: EXPERIMENTAL
Intervention: Sildenafil treatment for 12 weeks in HF+EOV subjects
Number of subjects: 56
Study: 18632217

Group type: EXPERIMENTAL
Intervention: RT-PET
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: RT-MID
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: RT-EXP
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: RT-INS
Number of subjects: 16

Group type: COMPARATOR
Intervention: D-PET
Number of subjects: 16
Study: 17369602

Group type: EXPERIMENTAL
Intervention: Doxorubicin (A)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Docetaxel (T)
Number of subjects: 326
Study: 15791370

Group type: EXPERIMENTAL
Intervention: Fast-track rehabilitation program
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard-care
Number of subjects: 52
Study: 11765304

Group type: EXPERIMENTAL
Intervention: Nonnicotine pharmacotherapy (bupropion, nortriptyline, moclobemide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine replacement therapy
Number of subjects: 0
Study: 9400053

Group type: EXPERIMENTAL
Intervention: Gadodiamide injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gadopentate dimeglumine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 100
Study: 7894226

Group type: EXPERIMENTAL
Intervention: MNNG (N‐methyl‐N'‐nitro‐N‐nitrosoguanidine) incubation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Exposure to environmental tobacco smoke (ETS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (unventilated room for 8 hours)
Number of subjects: 15
Study: 3322848

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac 75 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dipyrone 2 g
Number of subjects: 50
Study: 31863284

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg alone (Period 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg with rifampin 600 mg/day (Period 2)
Number of subjects: 0
Study: 30653533

Group type: EXPERIMENTAL
Intervention: mavoglurant
Number of subjects: 57

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 57
Study: 28228114

Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg TID
Number of subjects: 129

Group type: COMPARATOR
Intervention: Sildenafil 5 mg TID
Number of subjects: 129

Group type: COMPARATOR
Intervention: Sildenafil 1 mg TID
Number of subjects: 129
Study: 26379170

Group type: EXPERIMENTAL
Intervention: Annually assessed neuropsychological test scores
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Likelihood of low walking speed defined using individual-specific distributions of walking speed
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Likelihood of low computer use defined using individual-specific distributions of computer use
Number of subjects: 119

Group type: COMPARATOR
Intervention: Normal control (NC) group
Number of subjects: 119
Study: 24095005

Group type: EXPERIMENTAL
Intervention: Tramadol HCl 50 mg and adrenaline 0.0225 mg diluted to 1.8 mL by distilled water (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tramadol HCl 50 mg diluted to 1.8 mL by distilled water (Group B)
Number of subjects: 100
Study: 21426582

Group type: EXPERIMENTAL
Intervention: Continuity of midwifery care model and informational leaflet on managing weight gain in pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care plus the same informational leaflet on managing weight gain in pregnancy
Number of subjects: 0
Study: 19470838

Group type: EXPERIMENTAL
Intervention: Actovegin (2,000 mg/day intravenous infusions for 20 days, followed by 1,800 mg/day oral tablets for 140 days)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Placebo (same regimen as actovegin)
Number of subjects: 567
Study: 16960547

Group type: EXPERIMENTAL
Intervention: Episodic therapy with valacyclovir (500 mg twice daily for 5 days)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Suppressive therapy with valacyclovir (500 mg daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 80
Study: 15561445

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (TN)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Nicotine nasal spray (NS)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Both TN and NS
Number of subjects: 335
Study: 12564655

Group type: EXPERIMENTAL
Intervention: RSG+SU (4 mg rosiglitazone daily plus sulphonylurea)
Number of subjects: 348

Group type: COMPARATOR
Intervention: SU alone (control group)
Number of subjects: 348
Study: 9857665

Group type: EXPERIMENTAL
Intervention: Rifamazid (fixed-dose combination)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Free simultaneous combination of rifampicin and isoniazid
Number of subjects: 31
Study: 8567577

Group type: EXPERIMENTAL
Intervention: Heavy-resistance exercise protocol consisting of 3 sets of 10 repetition maximum resistances with 1-min rest between sets and exercises
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control day (nonexercise day)
Number of subjects: 7
Study: 2083193

Group type: COMPARATOR
Intervention: Diltiazem 120 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem titration from 240 to 360 mg/day (q12h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diltiazem titration from 180 to 270 to 360 mg/day (q8h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching regimen from q8h to q12h
Number of subjects: 0
Study: 493866

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 5
Study: 30714233

Group type: EXPERIMENTAL
Intervention: Nutraceutical combination containing polyphenols from Ascophyllum nodosum and Fucus vesiculosus and chromium picolinate
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Nutraceutical combination
Number of subjects: 65
Study: 28427580

Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Graft)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: DES-PCI (Drug-Eluting Stents)
Number of subjects: 1800
Study: 26003637

Group type: EXPERIMENTAL
Intervention: AN69 ST membrane filter
Number of subjects: 17

Group type: COMPARATOR
Intervention: Traditional AN69 membrane filter
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both AN69 ST and traditional AN69 membrane filters
Number of subjects: 17

Group type: COMPARATOR
Intervention: Vasoactive drugs usage in group II
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Coagulation indicators (APTT, PT, INR, PLT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Blood coagulation in filters
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bleeding complications
Number of subjects: 17
Study: 23455193

Group type: COMPARATOR
Intervention: Innovator drug (Singulair)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Locally manufactured drug (Montiget)
Number of subjects: 12
Study: 21300931

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 558

Group type: COMPARATOR
Intervention: No adjuvant chemotherapy
Number of subjects: 558
Study: 20183166

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (conducted once a week for three months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 0
Study: 16680955

Group type: EXPERIMENTAL
Intervention: Delayed skin grafting
Number of subjects: 54

Group type: COMPARATOR
Intervention: Early escharectomy
Number of subjects: 54
Study: 15515782

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) 5 million IU administered subcutaneously
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) 5 million IU
Number of subjects: 34
Study: 11429627

Group type: EXPERIMENTAL
Intervention: CHO (2.6 g kg‐1 carbohydrate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CHO + CAF (2.6 g kg‐1 carbohydrate + 6 mg kg‐1 caffeine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: FAT (1.2 g kg‐1 fat with 2000 U I.V. heparin)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: FAT + CAF (1.2 g kg‐1 fat with 2000 U I.V. heparin + 6 mg kg‐1 caffeine)
Number of subjects: 8
Study: 9359648

Group type: EXPERIMENTAL
Intervention: Local continuous (LC) injection of carboplatin (30 mg/day for 3, 7 or 14 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intravenous (IV) administration of carboplatin (210 mg)
Number of subjects: 26
Study: 7923492

Group type: EXPERIMENTAL
Intervention: Abdominal rectopexy (Wells or modified Ripstein's technique)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no bowel disturbances or anal symptoms)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Internal rectal procidentia rectopexy
Number of subjects: 31
Study: 3432859

Group type: EXPERIMENTAL
Intervention: Natural sleep (100 min)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-arousal condition (arousals 1/1 min)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-arousal condition (arousals 1/5 min)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Medium arousal condition (arousals 1/3 min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No sleep
Number of subjects: 40
Study: 30142760

Group type: COMPARATOR
Intervention: Ropivacaine plus normal saline (group R)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus dexmedetomidine (group RD)
Number of subjects: 50
Study: 27993104

Group type: EXPERIMENTAL
Intervention: T-2 toxin at 0.15, 0.33 and 1.82 mg kg‐1 body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deoxynivalenol (DON) at 0.13, 0.31 and 1.75 mg kg‐1 body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both mycotoxins (T-2 toxin and DON)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lowest dose of both mycotoxins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of both mycotoxins
Number of subjects: 0
Study: 25046787

Group type: EXPERIMENTAL
Intervention: 2 L/min of oxygen via nasal cannula
Number of subjects: 400

Group type: COMPARATOR
Intervention: Approximately 80% supplemental inspired oxygen after tracheal extubation
Number of subjects: 400
Study: 23462927

Group type: EXPERIMENTAL
Intervention: Caffeine-containing energy drink (3 mg/kg body mass)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22290036

Group type: EXPERIMENTAL
Intervention: Modified Stroop task
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Traditional Stroop task
Number of subjects: 31
Study: 18005493

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Solution-focused therapy
Number of subjects: 326
Study: 16491216

Group type: EXPERIMENTAL
Intervention: Patent blue dye (PBD)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Gamma probe detection (GPD)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both PBD and GPD
Number of subjects: 94
Study: 12854150

Group type: EXPERIMENTAL
Intervention: HBIG (200 IU intramuscularly every 4 weeks from 28 weeks of gestation)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lamivudine (100 mg orally every day from 28 weeks of gestation until 30 days after labor)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control (no specific treatment)
Number of subjects: 151
Study: 10868648

Group type: EXPERIMENTAL
Intervention: HHV‐7 infection
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CMV
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: HHV‐7
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CMV and HHV‐7 co-infection
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: HHV‐6
Number of subjects: 52
Study: 9352724

Group type: EXPERIMENTAL
Intervention: Patients with centrotemporal spikes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 8174495

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (1 g q 8 h)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Aminoglycoside + amoxycillin + clindamycin (C)
Number of subjects: 84
Study: 3580237

Group type: EXPERIMENTAL
Intervention: Midazolam given by infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam given as hourly intermittent injections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (infusion)
Number of subjects: 0
Study: 28870405

Group type: EXPERIMENTAL
Intervention: TMAO plasma levels measured at emergency department admission
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: TMAO plasma levels
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Higher age, higher body mass index, diabetes mellitus, chronic kidney disease
Number of subjects: 189
Study: 27514751

Group type: EXPERIMENTAL
Intervention: Multistate model to predict HF hospitalization and all-cause mortality
Number of subjects: 3834

Group type: EXPERIMENTAL
Intervention: Multistate model
Number of subjects: 3834
Study: 24684703

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Abdominal fetal electrocardiogram
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Electrohysterography
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Tocodynamometry
Number of subjects: 74
Study: 22744141

Group type: EXPERIMENTAL
Intervention: Parent + therapist enhanced milieu teaching (EMT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Therapist-only EMT
Number of subjects: 77
Study: 20577748

Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg daily for 5 days for up to six cycles)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Laparoscopic ovarian diathermy (LOD)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 260

Group type: COMPARATOR
Intervention: LOD
Number of subjects: 260
Study: 18930352

Group type: EXPERIMENTAL
Intervention: PENS
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: PENS+GCAE
Number of subjects: 200

Group type: COMPARATOR
Intervention: control-PENS
Number of subjects: 200

Group type: COMPARATOR
Intervention: control-PENS+GCAE
Number of subjects: 200
Study: 16520208

Group type: EXPERIMENTAL
Intervention: Continuous enhanced circulation therapy (CECT) system combined with low-dose aspirin (100 mg daily postoperatively)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg per day)
Number of subjects: 121
Study: 14743970

Group type: EXPERIMENTAL
Intervention: Colon-targeted tablets of metronidazole
Number of subjects: 6

Group type: COMPARATOR
Intervention: Immediate release tablets of metronidazole
Number of subjects: 6
Study: 10485772

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 50